Edesa Biotech, Inc. (EDSA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Edesa Biotech, Inc. (EDSA) closed at USD 2.67 on 2026-10-15, a change of +29 % over the past year, with a market capitalization of USD 34.72M.

Edesa Biotech, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Edesa Biotech, Inc. key figures

Previous close

USD 2.67 (2026-10-15)

1-year change

+29 %

Market cap

USD 34.72M

Enterprise value

USD 22.86M

P/E ratio (trailing)

-1.49

P/E ratio (forward)

-1.33

EPS (trailing)

-1.72

EPS (forward)

-1.93

PEG ratio

n/a

Price to book

62.68

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.95

Employees

17

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Edesa Biotech, Inc.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Edesa Biotech, Inc. and compare it with other stocks.